Your browser is no longer supported. Please, upgrade your browser.
Settings
GTXI GTx, Inc. daily Stock Chart
GTXI [NASD]
GTx, Inc.
Index- P/E- EPS (ttm)-2.01 Insider Own9.90% Shs Outstand22.38M Perf Week2.63%
Market Cap410.45M Forward P/E- EPS next Y-1.81 Insider Trans-0.54% Shs Float8.32M Perf Month19.48%
Income-41.40M PEG- EPS next Q-0.41 Inst Own42.30% Short Float18.00% Perf Quarter-1.40%
Sales- P/S- EPS this Y-43.40% Inst Trans28.28% Short Ratio11.49 Perf Half Y17.94%
Book/sh1.71 P/B10.73 EPS next Y2.20% ROA-89.80% Target Price37.50 Perf Year222.89%
Cash/sh2.04 P/C8.98 EPS next 5Y0.00% ROE-110.70% 52W Range5.57 - 23.40 Perf YTD44.30%
Dividend- P/FCF- EPS past 5Y23.20% ROI- 52W High-21.62% Beta1.41
Dividend %- Quick Ratio6.00 Sales past 5Y- Gross Margin- 52W Low229.36% ATR1.02
Employees27 Current Ratio6.00 Sales Q/Q- Oper. Margin- RSI (14)57.58 Volatility5.73% 6.97%
OptionableYes Debt/Eq0.00 EPS Q/Q-7.70% Profit Margin- Rel Volume0.67 Prev Close18.36
ShortableYes LT Debt/Eq0.00 EarningsAug 13 Payout- Avg Volume130.39K Price18.34
Recom1.00 SMA205.12% SMA507.43% SMA20016.09% Volume87,852 Change-0.11%
Mar-05-18Reiterated Stifel Buy $16 → $45
Nov-21-17Initiated Robert W. Baird Outperform $17
Nov-09-17Initiated Stifel Buy $16
Dec-09-16Reiterated Jefferies Hold $10 → $7
Apr-05-13Initiated Stifel Buy $7
Oct-14-11Initiated Rodman & Renshaw Mkt Outperform $7
Jul-20-11Initiated Wedbush Outperform $13
Oct-27-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
May-26-10Reiterated Rodman & Renshaw Mkt Underperform $1.75 → $1.25
Mar-17-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1.75
Jan-26-09Reiterated Leerink Swann Mkt Perform $18 → $10
Jan-22-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
May-23-08Downgrade Cowen & Co Outperform → Neutral
Mar-25-08Initiated Rodman & Renshaw Mkt Outperform $22
Nov-07-07Reiterated Lazard Capital Buy $28 → $31
Nov-06-07Reiterated Broadpoint Capital Buy $26 → $29
Oct-11-07Initiated Wachovia Outperform
Sep-13-07Initiated First Albany Buy $26
May-10-07Initiated Citigroup Hold $24
Apr-30-07Downgrade Leerink Swann Outperform → Mkt Perform
Aug-14-18 07:07AM  GTx: 2Q Earnings Snapshot Associated Press
07:00AM  GTx Provides Corporate Update and Reports Second Quarter 2018 Financial Results Business Wire
Aug-13-18 09:45AM  VKTX: Data from P2 Trial of VK2809 in 4Q18 Zacks Small Cap Research
Jun-25-18 07:00AM  GTx Added to the Russell 3000® Index Business Wire
Jun-05-18 07:40AM  Detailed Research: Economic Perspectives on First Mid-Illinois Bancshares, GTx, Ferroglobe, SunOpta, Bandwidth, and Carbonite What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-31-18 07:00AM  GTx, Inc. to Participate in the Jefferies 2018 Global Healthcare Conference Business Wire
May-18-18 02:00PM  GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting Business Wire
May-16-18 10:59AM  Does GTx Incs (NASDAQ:GTXI) -71.74% Earnings Drop Reflect A Longer Term Trend? Simply Wall St. +10.69%
May-15-18 07:04AM  GTx: 1Q Earnings Snapshot Associated Press
07:00AM  GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results Business Wire
May-13-18 10:06AM  The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More Benzinga
Apr-16-18 07:00AM  GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at a Podium Presentation at 2018 AUA Annual Meeting Business Wire
Apr-13-18 08:15AM  Research Report Identifies Third Point Reinsurance, GTx, pdvWireless, ACM Research, Reading International, and Canadian National Railway with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-11-18 07:10AM  Blog Exposure - GTx Completed Patient Enrollment Several Months Ahead in the Phase-2 Clinical Trial of Enobosarm in SUI ACCESSWIRE
Apr-09-18 07:00AM  GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial, a Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence Business Wire
Mar-15-18 08:00AM  Report: Developing Opportunities within Odonate Therapeutics, Greenlight Reinsurance, Landmark Infrastructure Partners LP, GTx, First Mid-Illinois Bancshares, and iClick Interactive Asia Group Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-12-18 04:21PM  GTx reports 4Q loss Associated Press
04:05PM  GTx Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results Business Wire
Mar-05-18 04:40PM  Why Square, CF Industries Holdings, and GTx Jumped Today Motley Fool +38.31%
12:39PM  GTx shares surge 30% on incontinence trial results MarketWatch
10:43AM  GTx, Inc. (GTXI) Soars 25% in Light of Encouraging Data in SUI SmarterAnalyst
07:00AM  GTx Announced New Data Demonstrating Enobosarms Potential to Treat Stress Urinary Incontinence at SUFU 2018 Business Wire
Feb-22-18 04:00PM  GTx Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence Accepted for Podium Presentation at SUFU Business Wire
Jan-26-18 02:30PM  Chairwoman of the board? Memphis public companies talk top-level gender diversity American City Business Journals
Nov-16-17 05:14AM  GTx reports 3Q loss Associated Press -15.98%
Nov-14-17 04:05PM  GTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results Business Wire
Nov-08-17 07:30AM  GTx, Inc. to Participate in the Stifel 2017 Healthcare Conference Business Wire -7.97%
Sep-29-17 04:05PM  GTx Announces Closing of $48.5 Million Private Placement Business Wire
Sep-26-17 07:30AM  GTx Announces $48.5 Million Private Placement Business Wire
Sep-25-17 05:50PM  GTx Announces Webcast of Corporate Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-21-17 04:05PM  GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City Business Wire
Sep-14-17 05:50PM  GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down Zacks
Sep-13-17 07:00AM  GTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence Business Wire -8.91%
Aug-14-17 10:09PM  GTx reports 2Q loss Associated Press
07:00AM  GTx Provides Corporate Update and Reports Second Quarter 2017 Financial Results Business Wire
Jul-12-17 01:42PM  GTx Discusses Key Goals with WSA Marketwired
Jun-13-17 10:14AM  GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up Zacks -21.63%
08:00AM  Today's Research Reports on Stocks to Watch: Xbiotech and GTx Accesswire
Jun-12-17 07:00AM  GTx Announces Positive Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence Business Wire +99.03%
May-15-17 07:10AM  GTx reports 1Q loss Associated Press
07:00AM  GTx Provides Corporate Update and Reports First Quarter 2017 Financial Results Business Wire
May-11-17 07:00AM  GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society Annual Meeting Business Wire -5.66%
May-03-17 07:00AM  GTx Announces Results from Preclinical Studies of SARMs in Duchenne Muscular Dystrophy Models Published in Human Molecular Genetics Business Wire
Mar-30-17 01:04PM  GTX INC /DE/ Financials
Mar-15-17 07:40AM  GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:12AM  GTx reports 4Q loss Associated Press
07:07AM  Q4 2016 GTX Inc Earnings Release - Before Market Open
07:00AM  GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results Business Wire
Mar-07-17 07:00AM  GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017 Business Wire -8.22%
Jan-09-17 04:31PM  GTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers -5.05%
Dec-21-16 12:16PM  GTX INC /DE/ Files SEC form 8-K, Other Events -12.48%
Dec-16-16 05:24AM  Is GTx, Inc. (GTXI) A Good Stock To Buy? Insider Monkey
05:24AM  Is GTx, Inc. (GTXI) A Good Stock To Buy? at Insider Monkey
Dec-08-16 03:13PM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits +5.18%
07:00AM  GTx Reports Results from Ongoing Enobosarm Phase 2 Clinical Trial in ER+/AR+ Breast Cancer Business Wire
Dec-06-16 10:20AM  GTx Declares 1-For-10 Reverse Stock Split (GTXI) Investopedia
10:20AM  GTx Declares 1-For-10 Reverse Stock Split (GTXI) at Investopedia
Dec-05-16 04:07PM  GTX INC /DE/ Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statement -14.10%
08:34AM  GTx, Inc. Announces 1-for-10 Reverse Stock Split Business Wire
Dec-01-16 08:38AM  GTx, Inc. :GTXI-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 Capital Cube
08:38AM  GTx, Inc. :GTXI-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Nov-28-16 10:25AM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits -7.08%
07:00AM  Enobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing Phase 2 Clinical Trial in ER+/AR+ Breast Cancer Business Wire
Nov-23-16 07:00AM  GTx Announces Webcast of Corporate Presentation at the 28th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-17-16 02:31PM  Heres What To Look For When The Real GTx, Inc. (GTXI) Data Hits at Insider Monkey
08:15AM  Blog Coverage GTx Inc. Enobosarm Achieves Stage 1 Milestone Accesswire
Nov-16-16 07:31AM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits +7.32%
07:00AM  GTx Achieves Second Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer Business Wire
Nov-11-16 07:00AM  GTx Announces Webcast of Corporate Presentation at the Stifel 2016 Healthcare Conference Business Wire
Nov-07-16 05:24PM  GTX INC /DE/ Files SEC form 10-Q, Quarterly Report
Nov-03-16 07:35AM  GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -7.89%
07:06AM  GTx reports 3Q loss
07:00AM  GTx Provides Corporate Update and Reports Third Quarter 2016 Financial Results Business Wire
Oct-18-16 05:27PM  Insider Invests in GTx
Oct-12-16 07:10AM  GTX INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financial Cond
07:00AM  GTx Announces $14.0 Million Registered Direct Common Stock Offering Business Wire
Sep-08-16 11:26AM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits +23.81%
07:00AM  GTx Achieves Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer Business Wire
Sep-02-16 07:00AM  GTx Announces Webcast of Corporate Presentation at Bairds 2016 Healthcare Conference Business Wire
Sep-01-16 07:32AM  GTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers
07:00AM  GTx Appoints Dr. Garry Neil to Board of Directors Business Wire
Aug-11-16 03:19PM  Nvidia: 'GTX1080 Will Power Them to Blow Away Q2 Estimate, Says M Science at Barrons.com
Aug-09-16 07:31AM  GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:09AM  GTx reports 2Q loss
07:00AM  GTx Provides Corporate Update and Reports Second Quarter 2016 Financial Results Business Wire
Jun-22-16 10:01AM  GTX INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tran
Jun-21-16 08:15AM  GTx (GTXI) Shows Strength: Stock Adds 11.2% in Session
Jun-08-16 06:07PM  GTx, Inc. :GTXI-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016
Jun-02-16 07:00AM  GTx Announces Webcast of Corporate Presentation at Jefferies 2016 Global Healthcare Conference Business Wire
May-16-16 07:00AM  GTx Announces Webcast of Corporate Presentation at the UBS Global Healthcare Conference 2016 Business Wire
May-10-16 07:32AM  GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:14AM  GTx posts 1Q profit
07:07AM  Q1 2016 GTX Inc Earnings Release - Before Market Open
07:00AM  GTx Provides Corporate Update and Reports First Quarter 2016 Financial Results Business Wire
May-09-16 05:16PM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  GTx Announces Presentation of Preclinical Data Demonstrating the Ability of SARDs to Degrade and Inhibit the Androgen Receptor at the American Urological Association Annual Meeting Business Wire
Apr-27-16 07:00AM  GTx, Inc. to Report First Quarter 2016 Financial Results on May 10, 2016 Business Wire
Apr-06-16 05:24PM  Edited Transcript of GTXI earnings conference call or presentation 3-Mar-16 2:00pm GMT
Mar-15-16 04:18PM  GTX INC /DE/ Files SEC form 10-K, Annual Report
Mar-03-16 09:00AM  GTX Inc Earnings Call scheduled for 9:00 am ET today
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wills Robert JamesExecutive ChairmanJun 26Buy16.755,00083,750137,344Jun 26 11:21 AM
DOGGRELL HENRY PATTONVP, Chief Legal OfficerJun 20Sale19.017,351139,70843,630Jun 22 05:16 PM
Shackelford Jason TPrin Fin. & Acct. OfficerJun 20Sale19.019,279176,35019,453Jun 22 05:15 PM
Shackelford Jason TPrin Fin. & Acct. OfficerJan 05Sale11.333,09035,02428,732Jan 09 06:12 PM
HANOVER MARC STEVENChief Executive OfficerJan 05Sale11.337,30982,845124,362Jan 09 06:12 PM
DOGGRELL HENRY PATTONVP, Chief Legal OfficerJan 05Sale11.334,96556,27750,981Jan 09 06:11 PM